



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

|                                |   |                            |
|--------------------------------|---|----------------------------|
| <b>Summary for ARTG Entry:</b> | 228309  | METAGENICS LIPOIC ACID 600 |
| <b>ARTG entry for</b>          | Medicine Listed                                 |                            |
| <b>Sponsor</b>                 | Metagenics (Aust) Pty Ltd                       |                            |
| <b>Postal Address</b>          | PO Box 675, VIRGINIA BC, QLD, 4014<br>Australia |                            |
| <b>ARTG Start Date</b>         | 23/09/2014                                      |                            |
| <b>Product Category</b>        | Medicine  |                            |
| <b>Status</b>                  | Active  |                            |
| <b>Approval Area</b>           | Listed Medicines                                |                            |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . METAGENICS LIPOIC ACID 600

| Product Type            | Effective Date |
|-------------------------|----------------|
| Single Medicine Product | 11/02/2020     |

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support natural liver cleansing/detoxification processes  
Maintain/support energy production  
Maintain/support liver health  
Aid/assist/helps glucose/sugar/carbohydrate metabolism

### Indication Requirements

Product presentation must not imply or refer to disease in any body organ, in particular the kidney or liver.  
Product presentation must not imply or refer to drugs/alcohol.  
If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.  
Product presentation must only refer to detoxification in relation to natural body processes.  
Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.  
Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

